The global metastatic castration-sensitive prostate cancer treatment market is witnessing significant expansion. This boom can be linked to factors such as an aging population, escalating prevalence of prostate cancer, and advancements in treatment methods. The market is further driven by increased understanding about the disease and its therapy op